日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

USP36 promotes tumorigenesis and tamoxifen resistance in breast cancer by deubiquitinating and stabilizing ERα

USP36 通过去泛素化和稳定 ERα 促进乳腺癌的肿瘤发生和他莫昔芬耐药性

Ting Zhuang #, Shuqing Zhang #, Dongyi Liu #, Zhongbo Li, Xin Li, Jiaoyan Li, Penghe Yang, Chenmiao Zhang, Jiayao Cui, Mingxi Fu, Fangyu Shen, Lei Yuan, Zhao Zhang, Peng Su, Jian Zhu, Huijie Yang

Regulation of the Hippo/YAP axis by CXCR7 in the tumorigenesis of gastric cancer

CXCR7对Hippo/YAP轴在胃癌发生发展中的调控

Tianshi Wang, Dehai Wang, Yanan Sun, Ting Zhuang, Xin Li, Huijie Yang, Yifeng Zang, Ziping Liu, Penghe Yang, Chenmiao Zhang, Jiayao Cui, Mingxi Fu, Shuqing Zhang, Peng Su, Zhongbo Li, Jian Zhu, Yinlu Ding

Phase separation in innate immune response and inflammation-related diseases

先天免疫反应和炎症相关疾病中的相分离

Ma, Huihui; Liu, Mingxi; Fu, Rao; Feng, Jia; Ren, Haoran; Cao, Jingyan; Shi, Ming

RNF31 represses cell progression and immune evasion via YAP/PD-L1 suppression in triple negative breast Cancer

RNF31 通过抑制 YAP/PD-L1 来抑制三阴性乳腺癌中的细胞进展和免疫逃避

Huijie Yang #, Min Xue #, Peng Su #, Yan Zhou #, Xin Li, Zhongbo Li, Yan Xia, Chenmiao Zhang, Mingxi Fu, Xiuxia Zheng, Guosheng Luo, Tian Wei, Xinxing Wang, Yinlu Ding, Jian Zhu, Ting Zhuang

RBCK1 is an endogenous inhibitor for triple negative breast cancer via hippo/YAP axis

RBCK1 是一种通过 Hippo/YAP 轴抑制三阴性乳腺癌的内源性抑制剂。

Zhongbo Li # ,Peng Su # ,Yinlu Ding # ,Honglei Gao # ,Huijie Yang ,Xin Li ,Xiao Yang ,Yan Xia ,Chenmiao Zhang ,Mingxi Fu ,Dehai Wang ,Ye Zhang ,Shu Zhuo ,Jian Zhu ,Ting Zhuang